| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A new dawn: inhaled antibiotics for patients with bronchiectasis
|
Grimwood, Keith
|
|
2019
|
7 |
3 |
p. 188-189
|
artikel
|
| 2 |
Asthma control: learning from Finland's success
|
Burki, Talha Khan
|
|
2019
|
7 |
3 |
p. 207-208
|
artikel
|
| 3 |
Common genetic variants in pulmonary arterial hypertension
|
Gu, Sue
|
|
2019
|
7 |
3 |
p. 190-191
|
artikel
|
| 4 |
Concerns over increased vaping in schoolchildren
|
Kirby, Tony
|
|
2019
|
7 |
3 |
p. 211-212
|
artikel
|
| 5 |
Correction to Lancet Respir Med 2019; 7: 115–28
|
|
|
2019
|
7 |
3 |
p. e12
|
artikel
|
| 6 |
Correction to Lancet Respir Med 2019; 7: 213–26
|
|
|
2019
|
7 |
3 |
p. e12
|
artikel
|
| 7 |
Delamanid: does it have a role in tuberculosis treatment?
|
Centis, Rosella
|
|
2019
|
7 |
3 |
p. 193-195
|
artikel
|
| 8 |
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial
|
von Groote-Bidlingmaier, Florian
|
|
2019
|
7 |
3 |
p. 249-259
|
artikel
|
| 9 |
Five Feet Apart—a story of living with cystic fibrosis
|
Hall, Phoebe
|
|
2019
|
7 |
3 |
p. 210
|
artikel
|
| 10 |
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis
|
Rhodes, Christopher J
|
|
2019
|
7 |
3 |
p. 227-238
|
artikel
|
| 11 |
Inhaled liposomal ciprofloxacin in patients with non-cystic fibrosis bronchiectasis and chronic lung infection with Pseudomonas aeruginosa (ORBIT-3 and ORBIT-4): two phase 3, randomised controlled trials
|
Haworth, Charles S
|
|
2019
|
7 |
3 |
p. 213-226
|
artikel
|
| 12 |
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial
|
Disselhorst, Maria J
|
|
2019
|
7 |
3 |
p. 260-270
|
artikel
|
| 13 |
Isoniazid preventive therapy for children in sub-Saharan Africa
|
Meremikwu, Martin
|
|
2019
|
7 |
3 |
p. 197-199
|
artikel
|
| 14 |
Lung transplantation for idiopathic pulmonary fibrosis
|
George, Peter M
|
|
2019
|
7 |
3 |
p. 271-282
|
artikel
|
| 15 |
New strategy for clean air in the UK—is it enough?
|
The Lancet Respiratory Medicine,
|
|
2019
|
7 |
3 |
p. 187
|
artikel
|
| 16 |
Our patients and our planet—holistic considerations for inhaler choice
|
Wilkinson, Alexander
|
|
2019
|
7 |
3 |
p. e11
|
artikel
|
| 17 |
Screening for tuberculosis: time to move beyond symptoms
|
Yoon, Christina
|
|
2019
|
7 |
3 |
p. 202-204
|
artikel
|
| 18 |
Smoking prevalence and chronic diseases in China
|
Shah, Asghar
|
|
2019
|
7 |
3 |
p. e10
|
artikel
|
| 19 |
Spotting the old foe—revisiting the case definition for TB
|
Houben, Rein M G J
|
|
2019
|
7 |
3 |
p. 199-201
|
artikel
|
| 20 |
Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?
|
Ghofrani, Hossein-Ardeschir
|
|
2019
|
7 |
3 |
p. 191-193
|
artikel
|
| 21 |
Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial
|
Sadushi-Kolici, Roela
|
|
2019
|
7 |
3 |
p. 239-248
|
artikel
|
| 22 |
The way forward for tuberculosis vaccines
|
White, Richard G
|
|
2019
|
7 |
3 |
p. 204-206
|
artikel
|
| 23 |
Towards optimal treatment for latent Mycobacterium tuberculosis infection
|
Abubakar, Ibrahim
|
|
2019
|
7 |
3 |
p. 195-197
|
artikel
|
| 24 |
Urgent action on antimicrobial resistance
|
Rahimi, Susan
|
|
2019
|
7 |
3 |
p. 208-209
|
artikel
|
Tijdschrift beschrijving